`
`Select Country
`
`Apotex Launches First Generic Version of Merck's Nasonex®
`
`For Media Inquiries, Please Contact:
`Jordan Berman
`Global Director,
`Corporate Communications
`
` 4100 Weston Road,
`
`Apotex Inc.
`
`
`North York,
`ON, M9L 1P9
`Canada
` 416-401-7487
` Email (/global/contact-us/jordan-berman)
`
` ✉
`
`Press Center
`
`Mar 24, 2016
`Apotex Launches First Generic Version of Merck's Nasonex®
`Toronto, ON – Apotex Inc. announced today that it has launched the first generic version of Merck's Nasonex nasal spray (mometasone furoate monohydrate) in the
`®
`United States.
`
`Apotex's mometasone furoate nasal spray is a once-daily anti-allergen indicated for treatment of nasal congestion. According to IMS Health, Nasonex had
`®
`approximately $955.5 million in sales in the 12 months ending January 2016.
`
`"We are very pleased to make a more affordable version of this important allergy medicine available to the US public. Apotex is dedicated to bringing high quality
`versions of complex generic products to market, and we are delighted that these efforts will generate substantial savings for the US health care system," said Apotex Chief
`Executive Officer and President, Dr. Jeremy B. Desai. "The amount of work required by all stakeholders to enable the launch of a first generic of this complexity cannot be
`overstated, and we appreciate the role of everyone involved, including the FDA who provided steady guidance throughout the development process," Desai added.
`
`FDA's approval of the company's generic version of Nasonex follows Apotex's successful Hatch-Waxman challenge of US Patent No. 6,127,353 (the '353 patent), which
`®
`Merck claimed covered the active ingredient. In June 2012, the US District Court for the District of New Jersey found that Apotex's product did not infringe the '353
`patent. The decision was upheld in June 2013 by the Federal Circuit.
`About Apotex
`Apotex is the 7th largest generic pharmaceutical company globally (according to IMS Health) with over 10,000 employees and estimated sales of approximately $2 billion.
`The company's US headquarters is based in Weston, Florida. With its worldwide manufacturing sites, Apotex can produce up to 24 billion dosages per year. It produces
`300 medicines in 4,000 dosages and formats that are exported to 115 countries. It has 500 products under development and will spend $2 billion over the next 10 years
`on research and development.
`
`-30-
`
`Jordan Berman
`Global Director, Corporate Communications
`Apotex Inc.
`Direct: 416-401-7487
`Mobile: 647-272-2287
`Email (/global/contact-us/jordan-berman)
`
`Legal & Copyright Terms (/global/legal-copyright-terms) | Privacy Policy (/global/privacy-policy) | Global Business Ethics & Compliance (/global/global-business-ethics-
`compliance) | Public Advisories (/global/public-advisories)
`
`About Us
`(/global/about-
`us)
`About Apotex
`(/global/about-
`us/about-apotex)
`Corporate
`Responsibility
`(/global/about-
`us/corporate-
`responsibility)
`Our Leadership
`(/global/about-
`us/our-
`leadership)
`
`Products
`(/global/products)
`
`Healthcare
`Professionals
`(/global/healthcare-
`professionals)
`
`R & D (/global/r-
`n-d)
`Research &
`Development
`(/global/r-n-
`d/research-and-
`development)
`Bioequivalence
`(/global/r-n-
`d/bioequivalence)
`Clinical Studies
`(/global/r-n-
`d/clinical-studies)
`
`Business Opportunities
`(/global/business-
`opportunities)
`International Business
`Development Opportunities
`(/global/business-
`opportunities/international-
`business-development-
`opportunities)
`Co-Development
`(/global/business-
`opportunities/co-development)
`Out-Licensing in EMEA
`(/global/business-
`
`http://www1.apotex.com/global/about-us/press-center/2016/03/24/apotex-launches-first-generic-version-of-mercks-nasonex
`
`Careers
`(/global/careers)
`
`Contact Us
`(/global/contact-
`us)
`Apotex
`Worldwide
`(/global/contact-
`us/apotex-
`worldwide)
`
`Exhibit 1106
`IPR2017-00807
`ARGENTUM
`1/1
`
`000001
`
`